Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

(Reuters) -Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

(Reuters) -Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader ...

The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...